Rodman & Renshaw Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Monopar Therapeutics with a Buy rating and set a price target of $50.
October 11, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Monopar Therapeutics with a Buy rating and a price target of $50, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a high price target suggests confidence in Monopar Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100